ストックスクリーナーアプリを入手
1.07
3.60%
-0.04
Cel-Sci Corp. (CVM) 最新ニュース
Why Did CEL-SCI Stock Plunge After Its Latest Offering - Kavout | AI
CVM: CEL-SCI Partners with Saudi Amarox for Multikine Launch - GuruFocus
CEL-SCI signs distribution deal with Saudi Amarox for Multikine - Investing.com
CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care - The Joplin Globe
CEL-SCI Corp (CVM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CEL-SCI Corp (CVM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CVM stock sinks in pre-market trading after announcing second equity raise for its cancer drug in just over a month - MSN
CEL-SCI Corp (CVM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CEL-SCI Corp (CVM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CEL-SCI Corp (CVM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CEL-SCI Corp (CVM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BRIEF-CEL-SCI Announces Closing Of Offering - Dailyhunt
CEL-SCI Corp (CVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CEL-SCI Corp (CVM) Institutional Confidence - TradingKey
CEL-SCI Corp (CVM) Valuation: PE, PB & Fair Value Analysis - TradingKey
CEL-SCI Corporation Announces $2.5 Million Stock Offering to Advance Multikine Cancer Immunotherapy 1 - Minichart
CEL-SCI closes $2.5M stock offering at $1 per share By Investing.com - Investing.com South Africa
CEL-SCI (CVM) Advances Multikine for Head and Neck Cancer - GuruFocus
CEL-SCI Completes $2.5M Stock Offering at $1.00, Engages ThinkEquity as Placement Agent - TradingView
CEL-SCI (NYSE American: CVM) prices $2.5M best-efforts stock offering - Stock Titan
CEL-SCI closes $2.5M stock offering at $1 per share - Investing.com
CEL-SCI Announces Closing of Offering - Yahoo Finance
CEL-SCI to begin confirmatory study for head and neck cancer drug - Investing.com
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy - Yahoo Finance
[424B5] CEL SCI CORP Prospectus Supplement (Debt Securities) - Stock Titan
CEL-SCI Corporation (CVM) Prices Public Offering, Shares Drop in Premarket - GuruFocus
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month - Mena FN
CEL-SCI stock sale prices $2.5M to fund Multikine work - Stock Titan
CEL-SCI Corporation Announces Pricing of Offering - Yahoo Finance
CVM: CEL-SCI Partners with Saudi Amarox for Strategic Agreement - GuruFocus
CEL-SCI to formalize Saudi Arabia distribution agreement - Investing.com
Saudi cancer immunotherapy push brings CEL-SCI Multikine deal - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market SessionAditxt (NASDAQ:ADTX), Atossa Therapeutics - Benzinga
Cel-Sci Stock Slides 5.43% as Key Support Test LoomsBullish Pattern Stocks - newsline.com
CVM Technical Analysis | Trend, Signals & Chart Patterns | CEL-SCI CORP (NYSEARCA:CVM) - ChartMill
Cel-Sci (CVM) Holds Near Support as Biotech Stock Posts Modest GainChaikin Flow - newsline.com
CVM - Finviz
[RW] CEL SCI CORP SEC Filing - Stock Titan
CVM: CEL-SCI Advances Multikine Toward Regulatory Approval - GuruFocus
Cel Sci CEO Geert Kersten’s trust buys $360,000 in common stock By Investing.com - Investing.com South Africa
Cel Sci CEO Geert Kersten’s trust buys $360,000 in common stock - Investing.com Australia
Cel Sci Insider Bought Shares Worth $360,000, According to a Recent SEC Filing - marketscreener.com
CEL-SCI (NYSE: CVM) trust buys 300K restricted shares at $1.20 - Stock Titan
CEL-SCI adds Saudi partner, U.S. trial for head and neck cancer drug - Stock Titan
Cel-Sci: Fiscal Q2 Earnings Snapshot - cbs19news.com
CEL SCI CORP 1H 2026: Net loss $(10.94M), Diluted EPS $(1.35) — 10-Q Summary - TradingView
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 - marketscreener.com
CEL-SCI (NYSE: CVM) reports $10.9M loss and just $1.9M in cash - Stock Titan
CEL-SCI Partners with Amarox for Multikine Cancer Immunotherapy Commercialization in Saudi Arabia and GCC Region 12 - minichart.com.sg
CVM SEC FilingsCEL-SCI Corp 10-K, 10-Q, 8-K Forms - Stock Titan
0.46%
0.50%
大文字化:
|
ボリューム (24 時間):